CAMBRIDGE, Mass., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage...
Mean muscle content-adjusted dystrophin expression of 9.0% and unadjusted dystrophin of 5.5%, with high...
Designation highlights significant unmet needs in DMD; dystrophin data from potentially registrational...
Successful clinical translation of Wave’s RNA medicines platform in HD patients with WVE-003 provides further...
CAMBRIDGE, Mass., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.